Skip to website navigation Skip to article navigation Skip to content

A page refresh occures when a subject is selected.

Skip article navigation.

3. Notes

13. Other operating income/expenses

13. Other operating income/expenses

€ million

2020

2019

Provisions

- 15

15

Impairment trade receivable

- 4

- 4

Gain / Loss (-) on disposal of non-current assets

- 3

7

Reimbursement by third parties for development expenses

5

4

Grants received

18

15

Collaboration agreement for the development and commercialization of Evenity™

96

8

Other income / expenses (-)

- 2

3

Total other operating income / expenses (-)

95

48

The result of the collaboration agreement with Amgen for the development and commercialization of Evenity amounted to € 96 million income (compared to € 8 million income in 2019). All recharges of development and commercialization expenses to/ from Amgen are classified as other operating income/expenses. The equivalent total net recharges as per December 31, 2020 consisted of € 98 million marketing and selling income (€ 14 million in 2019) and € -2 million development expenses (€ -6 million in 2019).

The provisions are mainly related to VAT risks and grant recoverability risks.